Abstract
ABSTRACTThe optimal dose for treating patients with a molecularly targeted agent may differ according to the patient's individual characteristics, such as biomarker status. In this article, we propose a Bayesian phase I/II dose-finding design to find the optimal dose that is personalized for each patient according to his/her biomarker status. To overcome the curse of dimensionality caused by the relatively large number of biomarkers and their interactions with the dose, we employ canonical partial least squares (CPLS) to extract a small number of components from the covariate matrix containing the dose, biomarkers, and dose-by-biomarker interactions. Using these components as the covariates, we model the ordinal toxicity and efficacy using the latent-variable approach. Our model accounts for important features of molecularly targeted agents. We quantify the desirability of the dose using a utility function and propose a two-stage dose-finding algorithm to find the personalized optimal dose according to each patient's individual biomarker profile. Simulation studies show that our proposed design has good operating characteristics, with a high probability of identifying the personalized optimal dose. Supplementary materials for this article are available online.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
